ADARx Pharmaceuticals raises $200m in Series C financing round
The capital garnered from the Series C financing will be channelled towards further advancement of ADARx's ongoing clinical…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Aug 23
The capital garnered from the Series C financing will be channelled towards further advancement of ADARx's ongoing clinical…
09 Aug 23
Neopharm will be appointed as Amarin’s sole and exclusive distributor to import, register, distribute, and commercialise Vazkepa in…
09 Aug 23
The clinical trial comes after the company's Trial-Ready Screening Cohort Study conducted in 2022, which involved screening, enrolling,…
09 Aug 23
The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein…
09 Aug 23
FDA-approved generic for MRI procedures is fully substitutable for Gadavist
08 Aug 23
BioNTech will obtain rights to commercialise the DB-1305 worldwide, except in Mainland China, Hong Kong Special Administrative Region…
08 Aug 23
According to the terms of the agreement, Astellas will invest $25m to buy 8,333,333 shares of common stock…
08 Aug 23
Under the terms of the agreement, Nautic will acquire Tabula Rasa for $10.50 in cash per share and…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services
08 Aug 23
IPAX-2 is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external…
07 Aug 23
Zurzuvae causes central nervous system (CNS) depressant effects, and people who take the drug should not drive a…